Printer friendly

What does CRPC stand for?

CRPC stands for Castration-Resistant Prostate Cancer

This definition appears very frequently and is found in the following Acronym Finder categories:

  • Science, medicine, engineering, etc.

See other definitions of CRPC

Other Resources:
We have 67 other meanings of CRPC in our Acronym Attic

Samples in periodicals archive:

of Kentucky) considers the functional significance of targeting apoptosis for the treatment of prostate cancer, with the aim of translating current understanding of the molecular regulation of programmed mechanisms of cell death into a discovery platform, to allow pharmacological exploitation of therapeutic modalities to combat metastatic, castration-resistant prostate cancer.
a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that clinical data from the ARMOR1 Phase 1 study and preclinical data on the unique triple mechanism of action of galeterone (TOK-001) in patients with castration-resistant prostate cancer (CRPC), will be presented today by Adrian M.
Enzalutamide, a new type of hormone treatment, was assessed in 1,199 patients with metastatic castration-resistant prostate cancer that had previously received chemotherapy, in a multinational, randomised placebo-controlled trial sponsored by pharmaceutical companies Medivation and Astellas.
Abiraterone acetate is approved, in combination with prednisone or prednisolone, for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.
[2] In April 2011 abiraterone acetate was approved in the US by the Food and Drug Administration (FDA)for use in combination with prednisone or prednisolone for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC) who have received prior chemotherapy containing docetaxel.
A total of 1,195 men (mean age 69 years, about 90% white) with metastatic castration-resistant prostate cancer who had failed up to two chemotherapy regimens, one of which contained docetaxel, were randomized to one of two treatment arms.
New York) said it has ended a late-stage clinical trial of its cancer drug Sutent, after seeing no survival benefit for patients with castration-resistant prostate cancer.